These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 8751138)

  • 21. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of enzymes of drug metabolism.
    Meyer UA
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):449-59. PubMed ID: 9131484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
    Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
    J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
    Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.
    Daly AK
    Drug Metab Pers Ther; 2015 Sep; 30(3):165-74. PubMed ID: 25803091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
    Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
    Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 Drug Metabolizing Enzymes in Roma Population Samples: Systematic Review of the Literature.
    Szalai R; Hadzsiev K; Melegh B
    Curr Med Chem; 2016; 23(31):3632-3652. PubMed ID: 27516201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
    Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
    Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
    Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
    J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study of the molecular mechanism of human cytochrome P450 and genetic polymorphism of drug oxidative metabolizing enzyme].
    Zhao L; Lou YQ
    Sheng Li Ke Xue Jin Zhan; 1997 Jan; 28(1):35-40. PubMed ID: 10921075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic polymorphisms.
    Daly AK; Cholerton S; Gregory W; Idle JR
    Pharmacol Ther; 1993; 57(2-3):129-60. PubMed ID: 8361990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphism in alcohol-metabolizing enzymes, glutathione S-transferases and apolipoprotein E and susceptibility to alcohol-induced cirrhosis and chronic pancreatitis.
    Frenzer A; Butler WJ; Norton ID; Wilson JS; Apte MV; Pirola RC; Ryan P; Roberts-Thomson IC
    J Gastroenterol Hepatol; 2002 Feb; 17(2):177-82. PubMed ID: 11966948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes.
    Yamazaki H
    Chem Res Toxicol; 2017 Jan; 30(1):53-60. PubMed ID: 27750412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucuronosyltransferases.
    Batt AM; Magdalou J; Vincent-Viry M; Ouzzine M; Fournel-Gigleux S; Galteau MM; Siest G
    Clin Chim Acta; 1994 May; 226(2):171-90. PubMed ID: 7923812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpatient variability: genetic predisposition and other genetic factors.
    West WL; Knight EM; Pradhan S; Hinds TS
    J Clin Pharmacol; 1997 Jul; 37(7):635-48. PubMed ID: 9243358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.